Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study
Abstract Ascorbic acid represents an appealing option for clinicians to utilize in the context of the global COVID-19 pandemic due to its proposed clinical efficacy, relative safety, and low cost. The aim of this study was to evaluate the efficacy and safety of using ascorbic acid in supplemental do...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-09-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-96703-y |
id |
doaj-01acb48b22bb49dda4056fb524eebae5 |
---|---|
record_format |
Article |
spelling |
doaj-01acb48b22bb49dda4056fb524eebae52021-09-05T11:33:18ZengNature Publishing GroupScientific Reports2045-23222021-09-011111810.1038/s41598-021-96703-yAscorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched studyKhalid Al Sulaiman0Ohoud Aljuhani1Khalid Bin Saleh2Hisham A. Badreldin3Abdullah Al Harthi4Mohammed Alenazi5Aisha Alharbi6Rahmah Algarni7Shmeylan Al Harbi8Abdullah M. Alhammad9Ramesh Vishwakarma10Sarah Aldekhyl11Pharmaceutical Care Department, King Abdulaziz Medical CityDepartment of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz UniversityPharmaceutical Care Department, King Abdulaziz Medical CityPharmaceutical Care Department, King Abdulaziz Medical CityPharmaceutical Care Department, King Abdulaziz Medical CityCollege of Pharmacy, King Saud Bin Abdulaziz University for Health SciencesPharmaceutical Care Department, King Abdulaziz University HospitalPharmaceutical Care Department, King Abdulaziz University HospitalPharmaceutical Care Department, King Abdulaziz Medical CityDepartment of Clinical Pharmacy, College of Pharmacy, King Saud UniversityBiostatistics and Bioinformatics Department, King Abdullah International Medical Research CenterCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research CenterAbstract Ascorbic acid represents an appealing option for clinicians to utilize in the context of the global COVID-19 pandemic due to its proposed clinical efficacy, relative safety, and low cost. The aim of this study was to evaluate the efficacy and safety of using ascorbic acid in supplemental doses as adjunctive therapy for patients critically ill with COVID-19. This was a two-center, non-interventional, retrospective cohort study. All critically ill adult patients admitted to ICU with a confirmed COVID-19 diagnosis between March 1st and December 31st, 2020, were included in the final analysis. The study was conducted at two large governmental tertiary hospitals in Saudi Arabia. The purpose was to investigate the clinical outcomes of low-dose ascorbic acid as adjunctive therapy in COVID-19 after propensity score matching using baseline severity scores, systematic use of corticosteroids, and study centers. A number of 739 patients were included in this study, among whom 296 patients were included after propensity score matching. There was no association between the administration of ascorbic acid and in-hospital mortality or the 30-day mortality [OR (95% CI) 0.77 (0.47, 1.23), p value = 0.27 and OR (95% CI) 0.73 (0.43, 1.20), p value = 0.21, respectively]. Using ascorbic acid was associated with a lower incidence of thrombosis compared with the non-ascorbic-acid group [6.1% vs. 13% respectively; OR (95% CI) 0.42 (0.184, 0.937), p value = 0.03]. Low dose of ascorbic acid as an adjunctive therapy in COVID-19 critically ill patients was not associated with mortality benefits, but it was associated with a lower incidence of thrombosis. Further studies are required to confirm these findings.https://doi.org/10.1038/s41598-021-96703-y |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Khalid Al Sulaiman Ohoud Aljuhani Khalid Bin Saleh Hisham A. Badreldin Abdullah Al Harthi Mohammed Alenazi Aisha Alharbi Rahmah Algarni Shmeylan Al Harbi Abdullah M. Alhammad Ramesh Vishwakarma Sarah Aldekhyl |
spellingShingle |
Khalid Al Sulaiman Ohoud Aljuhani Khalid Bin Saleh Hisham A. Badreldin Abdullah Al Harthi Mohammed Alenazi Aisha Alharbi Rahmah Algarni Shmeylan Al Harbi Abdullah M. Alhammad Ramesh Vishwakarma Sarah Aldekhyl Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study Scientific Reports |
author_facet |
Khalid Al Sulaiman Ohoud Aljuhani Khalid Bin Saleh Hisham A. Badreldin Abdullah Al Harthi Mohammed Alenazi Aisha Alharbi Rahmah Algarni Shmeylan Al Harbi Abdullah M. Alhammad Ramesh Vishwakarma Sarah Aldekhyl |
author_sort |
Khalid Al Sulaiman |
title |
Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study |
title_short |
Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study |
title_full |
Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study |
title_fullStr |
Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study |
title_full_unstemmed |
Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study |
title_sort |
ascorbic acid as an adjunctive therapy in critically ill patients with covid-19: a propensity score matched study |
publisher |
Nature Publishing Group |
series |
Scientific Reports |
issn |
2045-2322 |
publishDate |
2021-09-01 |
description |
Abstract Ascorbic acid represents an appealing option for clinicians to utilize in the context of the global COVID-19 pandemic due to its proposed clinical efficacy, relative safety, and low cost. The aim of this study was to evaluate the efficacy and safety of using ascorbic acid in supplemental doses as adjunctive therapy for patients critically ill with COVID-19. This was a two-center, non-interventional, retrospective cohort study. All critically ill adult patients admitted to ICU with a confirmed COVID-19 diagnosis between March 1st and December 31st, 2020, were included in the final analysis. The study was conducted at two large governmental tertiary hospitals in Saudi Arabia. The purpose was to investigate the clinical outcomes of low-dose ascorbic acid as adjunctive therapy in COVID-19 after propensity score matching using baseline severity scores, systematic use of corticosteroids, and study centers. A number of 739 patients were included in this study, among whom 296 patients were included after propensity score matching. There was no association between the administration of ascorbic acid and in-hospital mortality or the 30-day mortality [OR (95% CI) 0.77 (0.47, 1.23), p value = 0.27 and OR (95% CI) 0.73 (0.43, 1.20), p value = 0.21, respectively]. Using ascorbic acid was associated with a lower incidence of thrombosis compared with the non-ascorbic-acid group [6.1% vs. 13% respectively; OR (95% CI) 0.42 (0.184, 0.937), p value = 0.03]. Low dose of ascorbic acid as an adjunctive therapy in COVID-19 critically ill patients was not associated with mortality benefits, but it was associated with a lower incidence of thrombosis. Further studies are required to confirm these findings. |
url |
https://doi.org/10.1038/s41598-021-96703-y |
work_keys_str_mv |
AT khalidalsulaiman ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT ohoudaljuhani ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT khalidbinsaleh ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT hishamabadreldin ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT abdullahalharthi ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT mohammedalenazi ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT aishaalharbi ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT rahmahalgarni ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT shmeylanalharbi ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT abdullahmalhammad ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT rameshvishwakarma ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT sarahaldekhyl ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy |
_version_ |
1717814115838197760 |